BAH

What BAH does

Pharma Deutschland e.V. (legally renamed from the historical Bundesverband der Arzneimittel-Hersteller e.V., still abbreviated "BAH" in some references) is the largest trade association of the pharmaceutical industry in Germany. It is a registered non-profit association (eingetragener Verein) under German law, funded by membership dues from pharmaceutical companies operating in Germany. The organization is headquartered in Berlin (Friedrichstraße 134), with a secondary office in Bonn and an EU-representation office in Brussels. Its primary purpose is to represent member-company interests in healthcare policy, regulatory affairs, and public debate. It serves a single vertical: pharmaceutical companies in Germany, both manufacturers of patented medicines and broader industry members.

The association's product portfolio is services-oriented rather than technology-oriented. Core offerings include professional consulting and expert guidance, standardized contract templates for clinical trials (for sponsors, trial centers, and CROs), the Wissenschafts- und Wirtschaftsdienst (WiDi) science and economics service, an in-house publication and fact-sheet library, position papers and statements addressed to legislators, and the Health Monitor program of representative surveys on healthcare and supply. Distribution is membership-gated and supplemented by a public-facing newsroom, newsletter, and social channels on LinkedIn, Instagram, and YouTube. The business model is non-profit membership dues plus fee-for-service work on WiDi projects and publications; no equity, debt, or external ownership is indicated.

Operationally the association is active across multiple contemporary policy fronts: the GKV-Beitragssatzstabilisierungsgesetz and broader GKV-Spargesetz, EU-level supply security (the "Health4EU" framing around the EU Biotech Act), PFAS restrictions, pediatric drug classification under § 35 Abs. 5a SGB V, and the EU Commission's consultation on overregulation ("Gold-Plating"). Governance is via a Vorstand (board) and member committees. The association is best understood as a sectoral lobbying and standards-setting body whose competitive position rests on incumbency, recognized regulatory standing, and accumulated proprietary deliverables rather than technology assets.

Name

BAH

Legal name

Pharma Deutschland e.V.

Website

https://bah-bonn.de

Company type

Private

Founded year

1954

Operating status

Operating

Headcount range

51–100 employees

Short description

Pharma Deutschland e.V. is the largest German pharmaceutical industry trade association, funded by member dues and providing advocacy, regulatory consulting, clinical trial standard contracts, and publications to pharma companies in Germany. It operates from Berlin, Bonn, and Brussels.

Ownership category

akta.pro rank

Product category

Pharmaceutical Industry Association

NAICS

Professional Organizations (813920)

SIC

Services-Membership Organizations (8600)

akta.pro primary industry

Health, Pharmaceuticals & Medical Devices Regulatory Cooperation (BPADANAJ)

akta.pro secondary industries

Access Policy, Advocacy & Stakeholder Management (HLAIAKAL), Global Supply Chain, Procurement & Market-Shaping Partnerships (Medicines/Diagnostics/Vaccines) (HLAJAOAK)

Keywords

• Pharmaceutical industry association
• Healthcare policy advocacy
• Clinical trial contracts
• Pharmaceutical consulting services
• Industry representation

Headquarters

HQ city

Bonn

HQ country

Germany

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Infrastructure

Distribution channels1 record

Marketing channels5 records

Core offering

Pharma Deutschland e.V. is the largest industry association for the pharmaceutical industry in Germany, providing member companies with industry representation, policy advocacy, professional consulting, standardized clinical trial contract templates, scientific and economic services (WiDi), publications, position papers, and representative health monitoring surveys.

Product overview

Pharma Deutschland e.V. is a pharmaceutical industry association (Branchenverband) rather than a product company. It offers membership services to pharmaceutical companies, providing professional representation, expert consulting, standard contract templates for clinical trials, scientific and economic services (WiDi), publications including fact sheets and annual reports, and position papers on healthcare policy. The association also conducts representative health surveys through its Health Monitor program.

Differentiator

Problem solved

Functional benefit

Products and services

• Pharma Deutschland Membership
• Scientific and Economic Service (WiDi)
• Standard Contract Templates for Clinical Trials
• Publications and Technical Knowledge
• Position Papers and Statements
• Health Monitor

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves6 records

Expansion highlights5 records

Others

• IGES Institut: German research and consulting institute focused on healthcare and pharma markets. Comparable in the sense that it produces health-market data, analysis and policy studies that overlap with Pharma Deutschland's WiDi and Health Monitor offerings, even though it operates as a commercial rather than membership-funded entity.
• ABDA (Bundesvereinigung Deutscher Apothekerverbände): German pharmacists' umbrella association. Adjacent rather than directly competing — represents the dispensing side of the value chain rather than manufacturers — but engages on overlapping German health-policy topics that Pharma Deutschland also addresses.

Broad incumbents

• IFPMA (International Federation of Pharmaceutical Manufacturers and Associations): Global pharma industry federation. Operates one level above Pharma Deutschland (international rather than national) but uses a comparable advocacy, policy and standards mandate and competes for the attention of multinational members headquartered in Germany.
• BIO (Biotechnology Innovation Organization): Largest US biotech industry trade association. Comparable as a pharma/biotech advocacy and member-services organization, and a reference point on biotech policy positioning that overlaps with Pharma Deutschland's Biotech Act and biotech roadmap work.
• EFPIA (European Federation of Pharmaceutical Industries and Associations): Pan-European pharma industry federation headquartered in Brussels. Comparable to Pharma Deutschland at the EU level — covers lobbying, policy and industry data — and effectively the Brussels-side counterpart that Pharma Deutschland coordinates with through its EU office.

Direct peers

• EUCOPE (European Confederation of Pharmaceutical Entrepreneurs): European association representing small to mid-sized innovative pharma and biotech companies. Comparable as a Brussels-based pharma advocacy body with overlapping member interests on EU regulatory and market-access topics where Pharma Deutschland also engages.
• Pro Generika e.V. German generics industry association. Operates in the same German advocacy landscape with a member-base and policy agenda that partially overlaps and partially diverges from Pharma Deutschland's.
• BPI (Bundesverband der Pharmazeutischen Industrie e.V.): The other major German pharmaceutical industry association, representing pharma companies operating in Germany. Direct competitor in advocacy and member services for the same German pharma member base, though with somewhat different segment focus.
• vfa (Verband forschender Arzneimittelhersteller e.V.): German association of research-based pharmaceutical companies, focused on innovative and biotech-driven manufacturers. Competes with Pharma Deutschland for representation of innovative pharma members and runs parallel advocacy on German and EU policy.

Regional players

• AESGP (Association of the European Self-Care Industry): European self-care and consumer health industry association. Comparable as a European pharma-adjacent trade body with policy advocacy on OTC, self-medication and switching — topics that intersect Pharma Deutschland's Selbstmedikation agenda.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@pharmadeutschland
• LinkedInlinkedin.com/company/PharmaDeutschland
• Instagraminstagram.com/pharmadeutschland
• Xx.com/bah_digital

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BAH